AI Articles and Analysis about Research and development

Gilead Sciences, a biopharmaceutical company founded in 1987, has emerged as a leader in the development of innovative therapies for a range of diseases, including HIV, liver diseases, and oncology. With a commitment to advancing the field of medicine, Gilead has increasingly recognized the vital role that AI plays in its operations. Gilead Sciences achieved an annual revenue of approximately $28.3 billion in 2024, driven by its robust portfolio, and employs around 18,000 people globally, reflecting its substantial size and reach within the biotech industry​.

As technology advances, the lines between mobile applications and medical devices are blurring in ways that have healthcare leaders, software developers, and regulators alike facing new and unprecedented challenges.

Lilly and Company is a global pharmaceutical corporation founded in 1876 and headquartered in Indianapolis, Indiana. The company has offices in 18 countries and sells its products in approximately 125 countries worldwide. As of 2024, Lilly employs over 38,000 people globally and has an annual revenue of $34.12 billion. 

This article/interview analysis is sponsored by BenevolentAI and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.

Dozens of GPT-driven products are already on the market, and hundreds more are in development. These tools collectively aim to revolutionize traditional roles and processes, transforming them into dynamic, parallelized workflows using variants of LLM models, such as AutoGPT. Tools like GitHub Copilot, powered by OpenAI's Codex, are demonstrating significant improvements in developer productivity, with some studies showing up to a 55% increase in task completion speed. 

This interview analysis is sponsored by Pieces and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.

According to research from the American Society for Biochemistry and Molecular Biology, nine out of 10 drugs fail to make it to market in the clinical trials process. Researchers in the cited studies found that 40-50% of these failures are due to a lack of clinical efficacy, meaning that the drug is not able to produce its intended effect in people, and 30% were due to unmanageable toxicity or side effects.

Far beyond surface-level 'chatbot' software, and other customer-facing support systems, the same generative AI (GenAI) capabilities having direct impacts across language workflows in front-office tasks in financial and legal services is also having a direct impact on how research teams in the life sciences space are targeting solutions for rare diseases and novel treatments.